Skip to content

Regencell Bioscience

US · RGC #2393 by market cap Listed 2021
4.18 -0.18 -4.13%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:34

Valuation each multiple against its own 5-year range

P/B ratio 182.96 Expensive vs history 69th percentile
5-year average 790.04 · #68 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -205.83 In line with history 41st percentile
5-year average -682.80
P/S ratio --
5-year average 0.00

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Regencell Bioscience (RGC) 2.07B -174.17 154.81 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value5.47 Economic moatNone UncertaintyVery High

Trading 30.8% below Morningstar's fair value estimate.

Fair value

Regencell Bioscience Holdings Ltd earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% discount to our quantitative fair value estimate of $5.47 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:34:41 · For reference only, not investment advice and not tailored to your situation.

Regencell Bioscience discussion 0 comments

Add a comment